Pharm - AntiVirals Flashcards

1
Q
  1. Explain why “selective toxicity” is more difficult with viruses than with bacteria.
A

Viruses replicate by co-opting the host cell’s metabolic machinery. As a result, there are fewer differences between viruses and their human hosts to exploit for drug development than between bacteria and humans.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q
  1. Explain the difficulties in developing drugs against viruses
A

It is difficult to develop anti-viral drugs because there is such a wide spectrum of heterogeneous agents.Another difficulty is that, due to the heterogeneous nature of viruses mentioned above, antiviral drugs are often effective against only a few viruses while most antibacterial drugs target multiple bacterial species.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q
  1. Give three indications for acyclovir
A

HSV, VZV, EBV

For HSV:
– Mucocutaneous herpetic lesions
– Genital herpes lesions
– Prophylaxis in AIDS and other immunocompromised patients.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q
  1. List two blood-related adverse effects of ganciclovir
A
  1. Leukopenia (low levels of leukocytes in blood)

2. Thrombocytopenia (low #’s of platelets in blood)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q
  1. Apply what could be monitored to determine the duration of foscarnet action to a clinically-relevant case scenario.
A

 Clearance primarily by the kidney and is directly proportionate to creatinine clearance.

 Drug Monitoring
 Daily creatinine and BUN(blood urine nitrogen) during induction*
 Calcium, magnesium, and phosphorus*
 Check Hgb/Hct monthly*
 Electrolyte disturbances, sometimes severe, can develop even after therapy is discontinued.*
 If maintenance therapy is used, check creatinine, BUN, and ions weekly.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Major toxicity of zanamavir and for what population it should not be prescribed

A

Zanamavir is a Neuraminidase inhbitor
 Bronchospasm, decline in respiratory function
 Not recommended in patients with underlying airway disease (COPD, asthma)
 If benefit > risk, use short acting bronchodialator prior to administration, monitor after use

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q
  1. Draw a diagram of antivirals working through viral versus host cell kinases, include the sites of action of four specific drugs.
A

Acyclovir: Phosphorylation by TK (thymidine kinase)
Ganciclovir: Phosphorylation by CMV protein kinase (UL97)

Zidovudine, Idoxuridine, Cytarabine, Vidarabine are activated by host cell kinases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q
  1. Explain why acyclovir is more selectively toxic than other antivirals.
A

The increased selectivity is partly a result of acyclovir’s initial phosphorylation by a viral TK that is absent in uninfected cells.
More selectively toxic than the drugs that require phosphorylation only by the host enzymes.
Acyclovir: Phosphorylation by TK (thymidine kinase)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q
  1. List three viruses that acyclovir can be used against
A

Herpes simplex virus
Epstein-Barr virus
Varicella-zoster

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q
  1. List two indications for valacyclovir.
A

Recurrent genital herpes

Varicella-Zoster infections.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q
  1. List two indications for famciclovir.
A

For the management of acute herpes zoster

- Suppression of recurrent genital herpes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q
  1. Apply the early symptoms and DOC for herpes encephalitis to a clinically-relevant case scenario.
A

Seizure, headache, decreased consciousness, fever, lethargy and disoriented. Left temporal lobe decreased density, lack of bacteria in CSF (+ red blood cells)

	Acyclovir		10 mg/kg IV Q 8 hr
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q
  1. Explain how ganciclovir is metabolized to an active form inside host cells.
A

For CMV
• Acts as an antimetabolite, which is phosphorylated first by viral (monophosphorylation) and then by cellular kinases (di –and tri phosphorylation) to form a nucleotide that inhibits DNA polymerase of CMV.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q
  1. Explain how cidofovir has selective toxicity.
A

– Cidofovir is activated by intracellular enzymes to form an inhibitor of DNA polymerases.
– 1000-fold more effective against the DNA polymerases of viruses such as herpes virus than against the DNA polymerase of the host cell.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q
  1. Explain what is unique about the metabolism requirement of foscarnet.
A

Inhibits (in vitro) viral DNA polymerase, RNA polymerase, or HIV RT directly, without requirement for activation by phosphorylation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q
  1. List four viruses attacked by foscarnet.
A
  1. HSV - HHV-6
  2. VZV - HBV
  3. CMV - HIV
  4. EBV
17
Q
  1. Give the CDC guideline treatments for influenza in adults.
A

Zanamivir if age >7 year
Oseltamivir if age > 1 year
Amantadine for influenza A if age >1
Rimantadine for influenza A in adults only

Antiviral drugs should also be considered for the treatment of:
• High risk persons aged >1 year with influenza infection < 48 hours after the onset of illness
• Seriously ill influenza infected hospital patients
• Family members of high risk individuals during local community influenza activity
• Low risk influenza infected individuals if adequate antiviral drug supplies

18
Q
  1. Explain the MOA of neuraminidase inhibitors. (Zanamivir & oseltamivir)
A
  1. Inhibit viral cleavage of sialic acid
  2. Inhibit the release of newly formed viruses
     Neuraminidase releases newly synthesized virus by cleaving sialic acid from host cell glycoproteins when budding.
19
Q
  1. Explain the site of action for palivizumab.
A
  1. Binds to fusion (F) protein of RSV. The fusion protein is outside of the coating of the virus. Prevents infection of host cell, reduce replication of respiratory syncytial virus (RSV) and spread to other cells
20
Q
  1. Explain the dosing and timing of palivizumab treatment for RSV.
A
  1. A prophylaxis treatment of several times a month. 15 mg/kg IM monthly x up to 5 doses during RSV season with 1st dose given just prior to RSV season
21
Q
  1. Explain who should avoid contact with people receiving ribavirin and why.
A

Synthetic nucleoside analogue (guanosine) that inhibits viral nucleic acid synthesis and decreases nucleotide pool

  1. Planning to get pregnant or pregnant should avoid direct care of patients receiving inhaled ribavirin (it is teratogenic)
    Even exposure to the air of someone being treated

Anyone with any pulmonary issues should not take due to toxicities.